Essex Bio-Technology

What is Essex Bio-Technology?

Essex Bio-Technology Limited is a venture capital-backed bio-pharmaceutical company that specializes in the development, manufacture, and commercialization of genetically engineered therapeutic fibroblast growth factors (FGF). Since its inception in 1998, they have successfully approved six flagship biologics across various therapeutic areas such as Ophthalmology, Dermatology, and Wound Healing.

With products distributed in over 13,500 hospitals and managed by 43 regional sales offices, they have established a significant market presence. Their commitment to innovation is evident through the maintenance of a robust pipeline of projects at various clinical stages.

Their research and development efforts are supported by their Research and Innovation Centers strategically located across China, Singapore, the United Kingdom, and the United States.

In terms of production capabilities, Essex has multiple production lines tailored to drug substances and Active Pharmaceutical Ingredients (API), including preservative-free fill-finish solutions for drug products. Their sales and marketing strategy has yielded a dominant position in growth factor therapeutic products.

The company prides itself on embracing innovation to create first-in-class and best-in-class products that address the healthcare challenges of tomorrow, today. Among their achievements, Essex Bio-Technology has been recognized in Forbes Asia's Best Under A Billion list, and they continue to contribute to the scientific community through presentations at major conferences and successful completion of clinical trials.

Their partnership strategy includes exclusive agreements with companies like Osteopore for distribution rights and Gunze Shenzhen for agency rights, an amendment agreement with Henlius for global co-development on age-related macular degeneration treatments, and securing exclusive global rights of SkQ1 from Mitotech for Ophthalmology.

Financially, they have reported steady increases in net profit and revenue, indicating a strong market performance and growth potential.